Gilteritinib, a dual FLT3/AXL inhibitor, is clinically effective for relapsed/refractory FLT3-mutated acute myeloid leukemia (AML) but is limited by severe hepatotoxicity. This study investigates the molecular mechanisms underlying gilteritinib-induced liver i... ...
